Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma.

Lanzi C, Dal Bo L, Favini E, Tortoreto M, Beretta GL, Arrighetti N, Zaffaroni N, Cassinelli G.

Cancers (Basel). 2019 Mar 22;11(3). pii: E408. doi: 10.3390/cancers11030408.

2.

Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.

Cassinelli G, Dal Bo L, Favini E, Cominetti D, Pozzi S, Tortoreto M, De Cesare M, Lecis D, Scanziani E, Minoli L, Naggi A, Vlodavsky I, Zaffaroni N, Lanzi C.

Cancer Lett. 2018 Feb 28;415:187-197. doi: 10.1016/j.canlet.2017.12.009. Epub 2017 Dec 7.

PMID:
29225052
3.

Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.

Cassinelli G, Favini E, Dal Bo L, Tortoreto M, De Maglie M, Dagrada G, Pilotti S, Zunino F, Zaffaroni N, Lanzi C.

Oncotarget. 2016 Jul 26;7(30):47848-47863. doi: 10.18632/oncotarget.10292.

4.

Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.

Zuco V, Cassinelli G, Cossa G, Gatti L, Favini E, Tortoreto M, Cominetti D, Scanziani E, Castiglioni V, Cincinelli R, Giannini G, Zunino F, Zaffaroni N, Lanzi C, Perego P.

Biochem Pharmacol. 2015 Mar 15;94(2):79-90. doi: 10.1016/j.bcp.2015.01.002. Epub 2015 Jan 16.

PMID:
25600908
5.

Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.

Lopergolo A, Nicolini V, Favini E, Dal Bo L, Tortoreto M, Cominetti D, Folini M, Perego P, Castiglioni V, Scanziani E, Borrello MG, Zaffaroni N, Cassinelli G, Lanzi C.

J Clin Endocrinol Metab. 2014 Feb;99(2):498-509. doi: 10.1210/jc.2013-2574. Epub 2013 Nov 25.

PMID:
24276455
6.

Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.

Cassinelli G, Lanzi C, Tortoreto M, Cominetti D, Petrangolini G, Favini E, Zaffaroni N, Pisano C, Penco S, Vlodavsky I, Zunino F.

Biochem Pharmacol. 2013 May 15;85(10):1424-32. doi: 10.1016/j.bcp.2013.02.023. Epub 2013 Mar 1.

PMID:
23466421
7.

Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.

Nicolini V, Cassinelli G, Cuccuru G, Bongarzone I, Petrangolini G, Tortoreto M, Mondellini P, Casalini P, Favini E, Zaffaroni N, Zunino F, Lanzi C.

Biochem Pharmacol. 2011 Oct 1;82(7):778-88. doi: 10.1016/j.bcp.2011.06.037. Epub 2011 Jul 2.

PMID:
21741956
8.

TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells.

Anania MC, Sensi M, Radaelli E, Miranda C, Vizioli MG, Pagliardini S, Favini E, Cleris L, Supino R, Formelli F, Borrello MG, Pierotti MA, Greco A.

Oncogene. 2011 Jul 7;30(27):3011-23. doi: 10.1038/onc.2011.18. Epub 2011 Feb 21.

PMID:
21339735
9.

The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition.

Giommarelli C, Zuco V, Favini E, Pisano C, Dal Piaz F, De Tommasi N, Zunino F.

Cell Mol Life Sci. 2010 Mar;67(6):995-1004. doi: 10.1007/s00018-009-0233-x. Epub 2009 Dec 29.

PMID:
20039095
10.

Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.

Zuco V, Supino R, Favini E, Tortoreto M, Cincinelli R, Croce AC, Bucci F, Pisano C, Zunino F.

Biochem Pharmacol. 2010 Feb 15;79(4):535-41. doi: 10.1016/j.bcp.2009.09.012.

PMID:
19765546
11.

Biological effects of a new vacuolar-H,-ATPase inhibitor in colon carcinoma cell lines.

Supino R, Scovassi AI, Croce AC, Dal Bo L, Favini E, Corbelli A, Farina C, Misiano P, Zunino F.

Ann N Y Acad Sci. 2009 Aug;1171:606-16. doi: 10.1111/j.1749-6632.2009.04705.x.

PMID:
19723111
12.

Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.

Cassinelli G, Ronchetti D, Laccabue D, Mattioli M, Cuccuru G, Favini E, Nicolini V, Greco A, Neri A, Zunino F, Lanzi C.

Biochem Pharmacol. 2009 Nov 1;78(9):1139-47. doi: 10.1016/j.bcp.2009.06.023. Epub 2009 Jun 23.

PMID:
19555670
13.

Gamma-glutamyltransferase-dependent resistance to arsenic trioxide in melanoma cells and cellular sensitization by ascorbic acid.

Giommarelli C, Corti A, Supino R, Favini E, Paolicchi A, Pompella A, Zunino F.

Free Radic Biol Med. 2009 Jun 1;46(11):1516-26. doi: 10.1016/j.freeradbiomed.2009.03.006. Epub 2009 Mar 17.

PMID:
19298852
14.

RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.

Cassinelli G, Favini E, Degl'Innocenti D, Salvi A, De Petro G, Pierotti MA, Zunino F, Borrello MG, Lanzi C.

Neoplasia. 2009 Jan;11(1):10-21.

15.

Cellular response to oxidative stress and ascorbic acid in melanoma cells overexpressing gamma-glutamyltransferase.

Giommarelli C, Corti A, Supino R, Favini E, Paolicchi A, Pompella A, Zunino F.

Eur J Cancer. 2008 Mar;44(5):750-9. doi: 10.1016/j.ejca.2008.02.010. Epub 2008 Mar 7.

PMID:
18314325
16.

Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies.

Supino R, Petrangolini G, Pratesi G, Tortoreto M, Favini E, Bo LD, Casalini P, Radaelli E, Croce AC, Bottiroli G, Misiano P, Farina C, Zunino F.

J Pharmacol Exp Ther. 2008 Jan;324(1):15-22. Epub 2007 Oct 1.

PMID:
17909082
17.

Effect of paclitaxel on intracellular localization of c-Myc and P-c-Myc in prostate carcinoma cell lines.

Supino R, Favini E, Cuccuru G, Zunino F, Scovassi AI.

Ann N Y Acad Sci. 2007 Jan;1095:175-81.

PMID:
17404030
18.

Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1.

Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, Laccabue D, Supino R, Belluco S, Favini E, Poletti A, Zunino F.

Mol Cancer Ther. 2006 Sep;5(9):2388-97.

19.

Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.

Petrangolini G, Cassinelli G, Pratesi G, Tortoreto M, Favini E, Supino R, Lanzi C, Belluco S, Zunino F.

Br J Cancer. 2004 Apr 5;90(7):1464-8.

20.

Subcellular localization of the camptothecin analogues, topotecan and gimatecan.

Croce AC, Bottiroli G, Supino R, Favini E, Zuco V, Zunino F.

Biochem Pharmacol. 2004 Mar 15;67(6):1035-45.

PMID:
15006540
21.

The nitroxide tempol induces oxidative stress, p21(WAF1/CIP1), and cell death in HL60 cells.

Gariboldi MB, Rimoldi V, Supino R, Favini E, Monti E.

Free Radic Biol Med. 2000 Oct 1;29(7):633-41.

PMID:
11033415
22.

New 1,4-anthracene-9,10-dione derivatives as potential anticancer agents.

Zagotto G, Supino R, Favini E, Moro S, Palumbo M.

Farmaco. 2000 Jan;55(1):1-5.

PMID:
10755224
23.

Long term results of corneal grafting in Fuchs' endothelial dystrophy.

Olsen T, Ehlers N, Favini E.

Acta Ophthalmol (Copenh). 1984 Jun;62(3):445-52.

PMID:
6380203

Supplemental Content

Loading ...
Support Center